The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease

Abstract

Serum levels of leptin and adiponectin had no significant alterations, whereas serum-resistin levels are significantly decreased after infliximab therapy in IBD patients, suggesting a possible proinflammatory status for resistin in IBD and a role as a marker of successful therapy.

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis

“…11 12 Consistent with our fi ndings, most previous studies found no effect of TNF inhibition on circulating adiponectin levels in RA. 37 44 45 Other studies have suggested an increase in adiponectin levels, 46 47 in the absence of an effect on mRNA adiponectin levels in subcutaneous fat biopsies. 47 Together, the effects of TNF inhibition on adiponectin levels are at present poorly understood.…”

“…These results are consistent with previous reports showing that serum resistin levels are correlated with markers of infl ammation in patients with RA. 36 37 We are the fi rst to report altered resistin levels after long-term treatment with GC. As resistin is mainly produced by macrophages 8 38 and a decrease in the number of macrophages in synovium is consistently associated with improvement after effective treatment in RA, 39 40 we hypothesise that the observed reduction in resistin levels may refl ect the decreased number of synovial macrophages.…”

The role of resistin as a regulator of inflammation: Implications for various human pathologies

“…In addition, resistin correlated with the disease activity score, white blood cell count, and CRP in patients with Crohn's disease [121,122]. In contrast to leptin and adiponectin, resistin significantly decreases after TNF-α blocking therapy in patients with inflammatory bowel diseases and has been proposed as a marker of successful therapy, similar to the patients with rheumatoid arthritis [123].…”

“…Resistin has been suggested as an independent predictor of disease activity in patients with inflammatory bowel disease and has been proposed as a marker of successful therapy [121,123]. Moreover, RELM-β has anti-parasitic effects and may play a role in the pathology of inflammatory bowel diseases.…”

“…Resistin significantly decreased after the TNF-α blocking therapy in patients with rheumatoid arthritis and inflammatory bowel disease [108,109,123]. Treatment of patients with the skin form of psoriasis with retinoids leads to a normalization of serum resistin levels [113].…”